By Grands Rapids Anonymous
Friday, October 1, 2021 at 1:14:00 P.M. EDT
(ZH) As we reported earlier this morning, Merck has released what experts say are “extremely positive” test results for a COVID anti-viral that cuts risk of hospitalization in half, while also dramatically reducing the risk of death. The data were so profoundly positive that an oversight board ended the trial, claiming that withholding the drug from patients in the placebo group would be “unethical.”
Merck says it can deliver 10MM doses of the new drug, called Molnupiravir, by the end of the year, by which it should be approved by the FDA and possibly foreign regulators as well (the wheels of bureaucracy are reportedly turning as quickly as they can). Merck is submitting an emergency application for authorization of the drug, and we may see it in use during the next two weeks. The regimen is 2 pills a day for 5 days, and it’s most helpful within 5 days of infection.
The news has sent US stocks into the green for the day, while shares of Merck briefly soared as much as 12%.
GRA: But what about all the people with two or three shots of cancer-causing, blood clot-inducing, myocarditic inflammatory poison in their bloodstream?
Oh, well.
--GRA
No comments:
Post a Comment